A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus-Reference-Cited by-同舟云学术

A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus

Published:2016-05-20 Issue:6 Volume:10 Page:947-955
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Lim Young-Suk,Ahn Sang Hoon,Lee Kwan Sik,Paik Seung Woon,Lee Youn-Jae,Jeong Sook-Hyang,Kim Ju-Hyun,Yoon Seung Kew,Yim Hyung Joon,Tak Won Young,Han Sang-Young,Yang Jenny C.,Mo Hongmei,Garrison Kimberly L.,Gao Bing,Knox Steven J.,Pang Phillip S.,Kim Yoon Jun,Byun Kwan-Soo,Kim Young Seok,Heo Jeong,Han Kwang-Hyub

Funder

Gilead Sciences Inc.

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-016-9726-5.pdf

Reference36 articles.

1. Lim YS. Current status of liver disease in Korea: hepatitis C. Korean J Hepatol 2009;15(Suppl 6):S25–S28

2. Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681–688

3. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107–115